Company Overview - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines that address serious diseases by correcting abnormal gene expression [1][3] - The company utilizes its proprietary Gene Traffic Control® platform to identify and validate drug targets within the chromatin regulatory system, with an initial emphasis on oncology [3] Upcoming Events - Management will participate in the Citizens Life Sciences Conference on May 7-8, 2025, in New York, NY, with a presentation scheduled for May 7, 2025, at 9:30 a.m. EST by CEO Adrian Gottschalk [1][2] - In addition to the conference, management will engage in one-on-one meetings on the same day [2] Product Development - Foghorn Therapeutics is developing multiple product candidates aimed at treating genetically determined dependencies within the chromatin regulatory system, particularly in the oncology sector [3] - The company's broad pipeline has the potential to significantly impact the lives of patients suffering from a variety of diseases [1]
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference